FIPO23 Phase I/II, multi center, Open Label, First-in-human, Dose Escalation and Expansion study to investigate the Safety, Pharmacokinetics, and anti-tumors efficacy of the glyco-humanized polyclonal antibody XON7 in patients with advanced or metastatic solid tumors.

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505266-29-00

Acronym

XT-23-01 / FIPO23

Enrollment

246

Registered

2023-09-11

Start date

2023-11-14

Completion date

Unknown

Last updated

2025-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or metastatic solid tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026